Phenotypes Associated with This Genotype

Genotype
MGI:5527337

• Allelic Composition: Col1a1^{tm1(tetO-EML4/ALK)Kkw}/Col1a1⁺; Tg(Scgb1a1-rtTA)1Jaw/0
• Genetic Background: involves: 129 * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:166724 )

• doxycycline-treated mice exhibit a median survival of 7 to 8 weeks

neoplasm

abnormal tumor pathology ( J:166724 )

• withdrawal of doxycycline leads to complete tumor regression

• ALK kinase inhibitor is a more effective therapy than chemotherapy in doxycycline-treated mice

increased lung tumor incidence ( J:166724 )

• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days

• however, withdrawal of doxycycline leads to complete tumor regression

increased lung carcinoma incidence ( J:166724 )

• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

growth/size/body

weight loss ( J:166724 )

• in tumor-bearing, doxycycline-treated mice in the first 4 weeks

respiratory system

respiratory system phenotype ( J:166724 )

N • untreated mice exhibit normal lung histology

increased lung tumor incidence ( J:166724 )

• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days

• however, withdrawal of doxycycline leads to complete tumor regression

increased lung carcinoma incidence ( J:166724 )

• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:166724
lung non-small cell carcinoma		DOID:3908		J:166724